Following a treat-to-target strategy resulted in remission at 24 months regardless of which of three different treatment plans (DMARD alone, DMARD plus prednisolone or DMARD plus etanercept) was used in a randomized, single-blinded study of 94 DMARD-naive patients with juvenile idiopathic arthritis (JIA). When averaged across the three groups, at 24 months 71% of patients had achieved inactive disease and 39% of patients had achieved drug-free inactive disease. Time-to-flare following DMARD discontinuation did not differ between the groups.
References
Original article
Hissink Muller, P. et al. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2018-213902 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. Treat-to-target possible for JIA. Nat Rev Rheumatol 14, 684 (2018). https://doi.org/10.1038/s41584-018-0119-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-018-0119-0